Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

This is a multicenter, Phase II, Chinese study assessing the efficacy and safety of neoadjuvant durvalumab and platinum-based Chemotherapy, given intravenously, followed by either surgery and adjuvant durvalumab or definitive CRT and consolidation durvalumab in participants with borderline resectable stage III NSCLC.